Pancreatic Cancer

Pancreatic cancer in brief

Pancreatic cancer is one of the most common cancers of the digestive tract. In Germany, about 20,000 people develop pancreatic cancer each year. The average age at diagnosis is over 70 for both women and men. Because the early stages often cause no symptoms or only nonspecific ones, the cancer is usually discovered late. Even so, current research has brought important advances in the treatment of pancreatic cancer.

Pancreatic cancer at a glance

New cases in Germany
About 20,000 people per year
Average age at diagnosis
Over 70, in both women and men
Most common form
Exocrine tumors, above all ductal adenocarcinoma (95 %)
Detection
Usually late, because early stages often cause no symptoms or only nonspecific ones

What exactly is pancreatic cancer?

The pancreas lies in the middle of the upper abdomen, behind the stomach. It produces for digesting food (exocrine function) as well as hormones that regulate blood sugar, above all insulin (endocrine function). In pancreatic cancer, abnormal cells multiply uncontrollably. Both the exocrine and the endocrine cells can be affected. Exocrine tumors, above all ductal adenocarcinoma, which arises from the cells of the gland's ducts, account for the vast majority of cases at 95 %. This article refers to this form.

Why do I have pancreatic cancer?

In principle, anyone can develop pancreatic cancer. Cancer develops when the genetic material of a cell is damaged and the cell then multiplies uncontrollably. The exact cause has not been fully established. However, both hereditary factors and cell-damaging influences from lifestyle are known risk factors. These include:

  • Excessive alcohol consumption
  • Smoking
  • Overweight
  • Type 2 diabetes mellitus
  • Chronic inflammation of the pancreas
  • Familial pancreatic cancer: two or more first-degree relatives (parents, siblings, children) have had pancreatic cancer.
  • Inherited genetic syndromes (rare): e.g. changes in the BRCA genes or Lynch syndrome; these raise the risk of various types of cancer, including pancreatic cancer.

Symptoms of pancreatic cancer

At the beginning of the disease, there are often no symptoms or only nonspecific ones, which makes early diagnosis difficult. In advanced stages, the following symptoms can occur:

  • Pain in the upper abdomen that radiates to the back (in a band-like pattern)
  • Nausea and vomiting
  • Digestive problems with fatty stools (pale, oily-looking, foul-smelling stools)
  • Weight loss
  • Newly developed diabetes mellitus (due to disrupted insulin production) – a warning sign especially in older people who are not overweight

In most cases, the cancer develops in what is known as the head of the pancreas. Because it lies next to the bile duct, the cancer can block the flow of bile there. This can cause the following symptoms, among others:

  • Jaundice (yellowing of the eyes and skin)
  • Itching all over the body
  • Pale-colored stools
  • Dark-colored urine

These symptoms can also occur with other illnesses. If you have newly developed symptoms like these, you should see a doctor promptly.

When is pancreatic cancer treated?

In general, pancreatic cancer is treated as soon as the diagnosis has been confirmed and the stage has been determined. Diagnosis relies on imaging methods such as ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound from inside the body (endoscopic ultrasound), as well as blood tests (the CA 19-9). If surgery is not performed right away, the diagnosis is confirmed by a tissue sample.

How is pancreatic cancer treated?

Pancreatic cancer is treated according to its stage. In addition, factors such as the patient's general condition and whether the tumor can be removed surgically (resectability) play a role in the treatment decision. In early stages, a cure is possible if the tumor can be completely removed by surgery.

  • Neoadjuvant chemotherapy: If the tumor is borderline operable or locally advanced, chemotherapy given before surgery can be used to try to shrink it so that it becomes operable.
  • Surgery: Different surgical procedures are used depending on where the tumor is located. Either the entire pancreas or part of it is removed. For the common tumor in the head of the pancreas, surrounding structures such as lymph nodes, the gallbladder and bile duct, the adjacent part of the small intestine (duodenum), and sometimes the lowest part of the stomach are also removed (Whipple procedure).
  • Adjuvant chemotherapy: After surgery, additional chemotherapy is given for about six months to lower the risk of the cancer coming back (recurrence) and to improve the chance of a cure.

If the tumor is far advanced or has spread to other parts of the body (metastases), surgery – and therefore a cure – is usually no longer possible. Palliative treatment is then given with the aim of prolonging life, relieving symptoms, and maintaining quality of life. The following treatment options are used:

  • Chemotherapy: Combination chemotherapy forms the foundation of treatment because it slows the growth of the cancer cells and prolongs life.
  • Radiation therapy: It can be used for localized symptoms, e.g. pain caused by the tumor.
  • Targeted therapy: Some cancer cells have specific changes in their genetic material (e.g. in the BRCA or RAS genes). A tissue sample (biopsy) and a molecular test can identify these features so that the tumor can be treated in a targeted way. Supportive measures such as pain management, digestive enzymes, and nutritional counseling are also important.

How exactly have clinical trials changed the treatment landscape for pancreatic cancer?

The current standard of care is based on the results of trials conducted in recent years with the aim of advancing the treatment of pancreatic cancer.

  • In 2013, the German CONKO-001 trial showed that additional (adjuvant) chemotherapy with gemcitabine after complete surgical removal of pancreatic cancer leads to better long-term survival than surgery alone. Adjuvant therapy almost doubled the 5-year survival rate (from 10.4 % to 20.7 %). A total of 368 patients were enrolled in the trial. (DOI: 10.1001/jama.2013.279201)
  • In 2018, the PRODIGE 24/CCTG PA.6 trial showed that adjuvant chemotherapy with a combination of several drugs (mFOLFIRINOX) extends overall survival from 35 months to 54.4 months compared with gemcitabine alone. A total of 493 patients were enrolled in the trial. (DOI: 10.1056/NEJMoa1809775)
  • In metastatic pancreatic cancer, too, the FOLFIRINOX chemotherapy regimen showed longer survival in 2011 than the standard chemotherapy at the time, gemcitabine (11.1 months compared with 6.8 months). The trial enrolled a total of 342 patients. (DOI: 10.1056/NEJMoa1011923)
  • The RASolute-302 trial in 2026 brought a major advance for many patients with pancreatic cancer. In this trial of 500 patients whose metastatic pancreatic cancer had progressed despite initial chemotherapy, the drug daraxonrasib – a tablet that blocks the RAS protein, which is altered in almost all pancreatic tumors – doubled overall survival compared with chemotherapy (13.2 months compared with 6.7 months). Daraxonrasib is now approved in the US, but not yet in Germany. (DOI: 10.1056/NEJMoa2605555)

Interested in taking part in clinical trials? Then take a look here at the current trials in Germany.

This information is not a substitute for a conversation with your doctor.